{"id":"https://openalex.org/W4393383333","doi":"https://doi.org/10.1158/1078-0432.c.7158228.v1","title":"Data from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort","display_name":"Data from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort","alternate_titles":[],"publication_year":2024,"publication_date":"2024-04-01","ids":{"openalex":"https://openalex.org/W4393383333","doi":"https://doi.org/10.1158/1078-0432.c.7158228.v1"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.c.7158228.v1","doi":"https://doi.org/10.1158/1078-0432.c.7158228.v1","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.c.7158228.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"parent_works":[],"lineage":["https://openalex.org/W4393383333"],"child_works_count":0,"type":"other","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1158/1078-0432.c.7158228.v1","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5063648563","display_name":"Akihito Kawazoe","orcid":"https://orcid.org/0000-0001-8632-3748","observed_orcids":["https://orcid.org/0000-0001-8632-3748"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Akihito Kawazoe","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-8632-3748","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030587345","display_name":"Noboru Yamamoto","orcid":"https://orcid.org/0000-0002-0787-2851","observed_orcids":["https://orcid.org/0000-0002-0787-2851"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Noboru Yamamoto","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-0787-2851","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060456937","display_name":"Naotoshi Sugimoto","orcid":"https://orcid.org/0000-0001-9579-690X","observed_orcids":["https://orcid.org/0000-0001-9579-690X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Naotoshi Sugimoto","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-9579-690X","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007258796","display_name":"Hisato Kawakami","orcid":"https://orcid.org/0000-0002-3280-4850","observed_orcids":["https://orcid.org/0000-0002-3280-4850"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Hisato Kawakami","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-3280-4850","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090217118","display_name":"Takashi Oshima","orcid":"https://orcid.org/0000-0001-5818-8649","observed_orcids":["https://orcid.org/0000-0001-5818-8649"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Takashi Oshima","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-5818-8649","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091701897","display_name":"Kensei Yamaguchi","orcid":"https://orcid.org/0000-0001-6887-5709","observed_orcids":["https://orcid.org/0000-0001-6887-5709"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kensei Yamaguchi","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-6887-5709","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022620188","display_name":"Kaori Hino","orcid":"https://orcid.org/0000-0001-9046-253X","observed_orcids":["https://orcid.org/0000-0001-9046-253X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kaori Hino","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-9046-253X","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082376679","display_name":"Motohiro Hirao","orcid":"https://orcid.org/0000-0002-6509-6416","observed_orcids":["https://orcid.org/0000-0002-6509-6416"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Motohiro Hirao","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-6509-6416","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043504350","display_name":"Yukinori Kurokawa","orcid":"https://orcid.org/0000-0002-2883-0132","observed_orcids":["https://orcid.org/0000-0002-2883-0132"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yukinori Kurokawa","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-2883-0132","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068742608","display_name":"Takeshi Kawakami","orcid":"https://orcid.org/0000-0001-9385-9516","observed_orcids":["https://orcid.org/0000-0001-9385-9516"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Takeshi Kawakami","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-9385-9516","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029101744","display_name":"Masahiro Tsuda","orcid":"https://orcid.org/0000-0001-6442-9250","observed_orcids":["https://orcid.org/0000-0001-6442-9250"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Masahiro Tsuda","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-6442-9250","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050468802","display_name":"Hiroki Hara","orcid":"https://orcid.org/0000-0003-3881-9815","observed_orcids":["https://orcid.org/0000-0003-3881-9815"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Hiroki Hara","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-3881-9815","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5093657619","display_name":"Shota Kaname","orcid":"https://orcid.org/0009-0008-4436-6027","observed_orcids":["https://orcid.org/0009-0008-4436-6027"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Shota Kaname","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0008-4436-6027","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017653943","display_name":"Daiko Matsuoka","orcid":"https://orcid.org/0000-0001-8250-7603","observed_orcids":["https://orcid.org/0000-0001-8250-7603"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Daiko Matsuoka","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-8250-7603","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075434012","display_name":"Yohei Otake","orcid":"https://orcid.org/0000-0001-5056-403X","observed_orcids":["https://orcid.org/0000-0001-5056-403X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yohei Otake","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-5056-403X","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033429911","display_name":"Keisuke Yasuda","orcid":"https://orcid.org/0009-0005-8324-272X","observed_orcids":["https://orcid.org/0009-0005-8324-272X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Keisuke Yasuda","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0005-8324-272X","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028292561","display_name":"Takao Takase","orcid":"https://orcid.org/0000-0002-4556-5035","observed_orcids":["https://orcid.org/0000-0002-4556-5035"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Takao Takase","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-4556-5035","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014310544","display_name":"Shuya Takashima","orcid":"https://orcid.org/0009-0004-7148-9250","observed_orcids":["https://orcid.org/0009-0004-7148-9250"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Shuya Takashima","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0004-7148-9250","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015177508","display_name":"Taro Semba","orcid":"https://orcid.org/0000-0003-0432-1138","observed_orcids":["https://orcid.org/0000-0003-0432-1138"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Taro Semba","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-0432-1138","affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5073330859","display_name":"Kei Muro","orcid":"https://orcid.org/0000-0002-5572-743X","observed_orcids":["https://orcid.org/0000-0002-5572-743X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kei Muro","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-5572-743X","affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10696","display_name":"Gastric Cancer Management and Outcomes","score":0.8773999810218811,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10696","display_name":"Gastric Cancer Management and Outcomes","score":0.8773999810218811,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.061900001019239426,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11752","display_name":"Cancer Treatment and Pharmacology","score":0.03200000151991844,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/eribulin","display_name":"eribulin","score":0.9520000219345093},{"id":"https://openalex.org/keywords/e7389-lf","display_name":"E7389-LF","score":0.9100000262260437},{"id":"https://openalex.org/keywords/liposomal-formulation","display_name":"liposomal formulation","score":0.9589999914169312},{"id":"https://openalex.org/keywords/nivolumab","display_name":"nivolumab","score":0.9599999785423279},{"id":"https://openalex.org/keywords/gastric-cancer","display_name":"gastric cancer","score":0.9779999852180481},{"id":"https://openalex.org/keywords/pd-1-inhibitors","display_name":"PD-1 inhibitors","score":0.8550000190734863},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.6759999990463257},{"id":"https://openalex.org/keywords/microtubule-dynamics-inhibitor","display_name":"microtubule dynamics inhibitor","score":0.8920000195503235},{"id":"https://openalex.org/keywords/objective-response-rate","display_name":"objective response rate","score":0.8880000114440918},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.9819999933242798},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.6809999942779541},{"id":"https://openalex.org/keywords/treatment-related-adverse-events","display_name":"treatment-related adverse events","score":0.7509999871253967},{"id":"https://openalex.org/keywords/neutropenia","display_name":"neutropenia","score":0.8930000066757202},{"id":"https://openalex.org/keywords/cd8-t-cells","display_name":"CD8+ T cells","score":0.7720000147819519},{"id":"https://openalex.org/keywords/vascular-markers","display_name":"vascular biomarkers","score":0.5230000019073486},{"id":"https://openalex.org/keywords/interferon-gamma","display_name":"interferon-gamma","score":0.6959999799728394},{"id":"https://openalex.org/keywords/biomarkers","display_name":"biomarkers","score":0.6549999713897705}],"concepts":[{"id":"https://openalex.org/C2776387010","wikidata":"https://www.wikidata.org/wiki/Q408717","display_name":"Eribulin","level":5,"score":0.9082130789756775},{"id":"https://openalex.org/C2780030458","wikidata":"https://www.wikidata.org/wiki/Q7041828","display_name":"Nivolumab","level":4,"score":0.7735854387283325},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7255966067314148},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5571209192276001},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.5480993390083313},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5066724419593811},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.48355528712272644},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.11257123947143555},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.06031954288482666},{"id":"https://openalex.org/C2775930923","wikidata":"https://www.wikidata.org/wiki/Q12859063","display_name":"Metastatic breast cancer","level":4,"score":0.059258848428726196}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1078-0432.c.7158228.v1","doi":"https://doi.org/10.1158/1078-0432.c.7158228.v1","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.c.7158228.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.1158/1078-0432.c.7158228.v1","doi":"https://doi.org/10.1158/1078-0432.c.7158228.v1","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.c.7158228.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4391380740","https://openalex.org/W4317863145","https://openalex.org/W4318932570","https://openalex.org/W4361950510","https://openalex.org/W3169189131","https://openalex.org/W4404001045","https://openalex.org/W4317863063","https://openalex.org/W4402220631","https://openalex.org/W4380995272","https://openalex.org/W4383815606"],"abstract_inverted_index":{"AbstractPurpose:":[0],"E7389-LF":[1,35,109,151,204,239],"is":[2],"a":[3,25,40,70,77],"liposomal":[4],"formulation":[5],"of":[6,20,34,84,192,220],"the":[7,18,50,55,85,133,146,156],"microtubule":[8],"dynamics":[9],"inhibitor":[10],"eribulin":[11],"and":[12,32,59,76,96,98,104,139,176,200,218,224,249],"has":[13],"shown":[14],"preliminary":[15],"efficacy":[16,31],"in":[17,36,112,152,205,240,244],"treatment":[19],"gastric":[21,51,66,247],"cancer.":[22],"Study":[23],"120,":[24],"phase":[26,87],"Ib/II":[27],"open-label":[28],"study,":[29],"assessed":[30,128],"safety":[33,95,252],"combination":[37,113,153,206,241],"with":[38,114,154,207,238,242,246,257],"nivolumab,":[39,155],"programmed":[41],"cell":[42],"death":[43],"(PD)-1":[44],"inhibitor.":[45],"This":[46],"report":[47],"focuses":[48],"on":[49],"cancer":[52],"cohort":[53],"within":[54],"expansion":[56,86],"phase.":[57],"Patients":[58,107],"Methods:":[60],"Eligible":[61],"patients":[62,148,245],"had":[63],"unresectable,":[64],"measurable":[65],"cancer,":[67,248],"progression":[68],"following":[69],"platinum":[71],"drug":[72],"plus":[73],"fluoropyrimidine":[74],"(1L),":[75],"taxane-containing":[78],"regimen":[79],"(2L).":[80],"The":[81,166,187],"primary":[82],"objective":[83,89,157],"was":[88,160,170,180,236],"response":[90,158],"rate,":[91],"secondary":[92],"objectives":[93,100],"included":[94,101],"PFS,":[97],"exploratory":[99],"overall":[102,178],"survival":[103,169,179],"biomarker":[105],"evaluation.":[106],"received":[108,150],"2.1":[110],"mg/m2":[111],"nivolumab":[115,208,243],"360":[116],"mg":[117],"every":[118,129],"3":[119],"weeks,":[120],"both":[121],"as":[122],"intravenous":[123],"infusions.":[124],"Tumor":[125],"responses":[126],"were":[127,142,195,254],"6":[130],"weeks":[131],"by":[132],"investigators":[134],"per":[135],"RECIST":[136],"v1.1.":[137],"Plasma":[138],"tumor":[140],"biomarkers":[141],"assessed.":[143],"Results:":[144],"In":[145],"31":[147],"who":[149],"rate":[159],"25.8%":[161],"[confidence":[162],"interval":[163],"(CI),":[164],"11.9\u201344.6].":[165],"median":[167,177],"progression-free":[168],"2.69":[171],"months":[172,182],"(95%":[173,183],"CI,":[174,184],"1.91\u20132.99)":[175],"7.85":[181],"4.47\u2013not":[185],"estimable).":[186],"most":[188],"common":[189],"treatment-related":[190],"TEAE":[191],"any":[193],"grade":[194],"neutropenia":[196],"(77.4%),":[197],"leukopenia":[198],"(74.2%),":[199],"decreased":[201],"appetite":[202],"(51.6%).":[203],"significantly":[209],"increased":[210],"CD8-positive":[211],"cells":[212],"at":[213],"C2D1":[214],"(P":[215],"=":[216],"0.039),":[217],"six":[219],"seven":[221],"vascular":[222],"markers":[223,227],"four":[225],"IFN\u03b3-related":[226],"showed":[228],"increases":[229],"from":[230],"C1D1.":[231],"Conclusions:":[232],"Promising":[233],"antitumor":[234],"activity":[235],"observed":[237],"no":[250],"new":[251],"signals":[253],"observed,":[255],"compared":[256],"either":[258],"monotherapy.":[259]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W4393383333","counts_by_year":[],"updated_date":"2026-11-17T12:49:18.490984","created_date":"2024-04-02T00:00:00"}
